A case-control study found that patients who developed colon cancer, particularly in the proximal colon, were more likely to have taken antibiotics, whereas antibiotic use was not associated with increased risk of rectal cancer.
A retrospective trial showed no increase in new corticosteroid therapy or disease-related hospitalization or surgery among patients who discontinued 5-aminosalycilate (5-ASA) therapy when initiating an anti-tumor necrosis factor (anti-TNF) agent.
The increase primarily occurred among people who reported drug use or homelessness.
The guideline focuses on oral and topical 5-aminosalicylic acid medications, rectal corticosteroids, and oral budesonide in patients with mild to moderate disease.
Although hypnotherapy did not improve quality of life, psychological symptoms, cognition, self-efficacy, or irritable bowel syndrome (IBS) symptoms significantly more than an educational support program, it may provide relief to patients by changing
In this Swedish case-control study, any previous GI infection and previous bacterial, parasitic, and viral GI infection were associated with higher risk for inflammatory bowel disease (IBD) versus controls.
In a meta-analysis of 22 studies in patients with nonalcoholic fatty liver disease (NAFLD), weight loss interventions were associated with improvements in alanine aminotransferase level, liver steatosis, histologic NAFLD activity score, and
An accompanying editorial said that based on the risk of gastrointestinal (GI) events found in this retrospective study, sodium polystyrene sulfonate should not be used to reduce serum potassium levels.
There was no significant difference in upper GI events between a pantoprazole group and a placebo group, although pantoprazole was associated with significantly reduced bleeding of gastroduodenal lesions, an industry-funded study found.
Infliximab may have been used inappropriately in Crohn's disease and underused in ulcerative colitis, according to the authors of an analysis of hospitalizations, intestinal resections, and drug costs related to inflammatory bowel disease (IBD).